A Study of LY4515100 in Healthy Participants

Part of paid clinical trials in Dallas, Texas.

Sponsor
Eli Lilly and Company
Study ID
NCT07339722
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • LY4515100 via SAD — DRUG
    given orally
  • LY4515100 via MAD — DRUG
    given orally

Study Details

The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 30 days and will include six overnight stays.

Key Dates

Start date
Jan 15, 2026
Status verified
Feb 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4515100 of Part A (SAD)
    Single-ascending doses of LY4515100 will be given orally
  • Experimental: LY4515100 of Part B (MAD)
    Multiple-ascending doses of LY4515100 will be given orally
  • Placebo Comparator: Placebo Part A
    Placebo will be given orally
  • Placebo Comparator: Placebo Part B
    Placebo will be given orally

Primary Outcome Measure

Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 [ Time Frame: Day 1 up to Day 30 ]

Central Contacts

  • There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDallasTexas75247
866-429-3700
Gene Voskuhl (PRINCIPAL_INVESTIGATOR)

Find similar trials in Dallas, TX

By research site
Fortrea Clinical Research Unit· Dallas, TX

Related Studies